UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Medline ® Abstract for Reference 16

of 'Enterotoxicity of chemotherapeutic agents'

16
TI
VEGF pathway inhibition by anticancer agent sunitinib and susceptibility to atherosclerosis plaque disruption.
AU
Ropert S, Vignaux O, Mir O, Goldwasser F
SO
Invest New Drugs. 2011 Dec;29(6):1497-9.
 
Patients treated with anti-VEGF agents are at increased risk for arterial thrombo-embolic events (ATEs). However, the pathophysiology of such acute vascular complications remains unclear. We report on a case of bowel infarction in a renal cancer patient treated with the anti-VEGF agent sunitinib. An abdominal CT-scan evidenced the rupture of an atherosclerotic plaque located at the emergence of the superior mesenteric artery. In view of this report, we suggest that evaluation of the risk of ATE in patients receiving anti-VEGF agents should include not only age and past history of ATE as suggested by previous studies, but also assessment of atherosclerotic lesions on CT-scan.
AD
Centre for Research on Angiogenesis Inhibitors (CERIA), Department of Medical Oncology, AP-HP, Cochin Teaching Hospital, UniversitéParis Descartes, 27, rue du faubourg saint Jacques, F75014, Paris, France.
PMID